Publications by Melanie Griffin - ePrints

Browsing publications by Melanie Griffin.

Newcastle Authors	Title	Year
Melanie Griffin Dr Claire Jennings Professor Gareth Veal	Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated acute myeloid leukemia	2021
Dr Britta Vormoor Professor Gareth Veal Melanie Griffin Professor Julie Irving Lynne Minto et al.	A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia	2017
Dr David Jamieson Dr Nicola Sunter Sara Muro Dr Nicola Cresti Julieann Sludden et al.	Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide	2017
Dr David Jamieson Melanie Griffin Julieann Sludden Dr Yvette Drew Dr Nicola Cresti et al.	A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours	2016
Professor Andrew Pearson Dr Quentin Campbell Hewson Professor Alan Boddy Melanie Griffin	A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study	2015
Dr David Jamieson Dr Jo Lee Dr Nicola Cresti Melanie Griffin Julieann Sludden et al.	Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil	2014
Dr David Jamieson Dr Nicola Cresti Julieann Sludden Melanie Griffin Nahed Hawsawi et al.	Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy	2011
Melanie Griffin Professor Alan Boddy Professor Andrew Pearson	Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia	2010
Julieann Sludden Melanie Griffin Mike Cole Dr Mark Verrill Dr David Jamieson et al.	Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide	2010
Professor Ruth Plummer Melanie Griffin Dr Sally Coulthard Julieann Sludden Professor Alan Calvert et al.	Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors	2009
Professor Ruth Plummer Professor Alan Boddy Melanie Griffin Dr Mark Verrill	A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies	2008
Professor Alan Boddy Melanie Griffin Julie Errington Professor Gareth Veal	Dosing of cancer patients with low or absent renal function	2007
Dr Jo Lee Dr Mark Verrill Julieann Sludden Melanie Griffin Sharon Erb et al.	Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer	2007
Professor Alan Boddy Julieann Sludden Melanie Griffin Professor Herbie Newell Professor Stephen O'Brien et al.	Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia	2007
Professor Alan Boddy Professor Ruth Plummer Julieann Sludden Melanie Griffin Dr Mark Verrill et al.	A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules	2005
Dr Ashraf Azzabi Dr Andrew Hughes Dr Paula Calvert Professor Ruth Plummer Melanie Griffin et al.	Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations	2005
Professor Gareth Veal Julie Errington Julieann Sludden Melanie Griffin Annie Parry et al.	Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry	2003
Julie Errington Professor Gareth Veal Julieann Sludden Melanie Griffin Professor Andrew Pearson et al.	Determination of the anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry	2003
Dr Andrew Hughes Dr Paula Calvert Dr Ashraf Azzabi Professor Ruth Plummer Melanie Griffin et al.	Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma	2002
Dr Andrew Simpson Dr Paula Calvert Julieann Sludden Professor Alan Boddy Melanie Griffin et al.	Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules	2002
Professor Gareth Veal Melanie Griffin Annie Parry Dr Juliet Hale Professor Andrew Pearson et al.	A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin	2001
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al.	Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer	2001
Professor Alan Boddy Dr Mark Verrill Julieann Sludden Melanie Griffin Kevin Fishwick et al.	Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate	2001
Dr Andrew Hughes Melanie Griffin Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al.	Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq(TM)) and paclitaxel	2000
Melanie Griffin Professor Alan Boddy	Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients	2000
Melanie Griffin Professor Alan Boddy	Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients	2000
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al.	Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer	2000
Dr Andrew Hughes Melanie Griffin Professor Alan Calvert Professor Herbie Newell Professor Alan Boddy et al.	Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days	1999
Dr Andrew Hughes Melanie Griffin Professor Alan Calvert Andrew Johnston Professor Herbie Newell et al.	Pharmacokinetic interactions in a phase I study of nolatrexed (AG337, THYMITAQ ^TM) and paclitaxel in patients with advanced solid tumours	1998
Professor Alan Boddy Melanie Griffin Dr Margaret Little Professor Andrew Pearson	Pharmacokinetics and blood distribution in paediatric patients of SPI-77: Cisplatin encapsulated in Stealth® liposomes	1998